American Vanguard Corporation
4.5900-0.31 (-6.33%)
Oct 29, 4:00:02 PM EDT · NYSE · AVD · USD
Key Stats
Market Cap
130.50MP/E (TTM)
-Basic EPS (TTM)
-4.47Dividend Yield
0%Recent Filings
8-K
Credit facility extended to 2026
American Vanguard amended its loan agreement on August 18, 2025, extending the maturity to December 31, 2026, while stepping down the revolving credit facility from $245 million through November 2025 to $180 million thereafter. Lenders hiked interest margins to 5.25% on SOFR loans starting October 1, 2025, and imposed minimum year-to-date EBITDA targets—$4.5 million by June 30, $9.5 million by September 30, and $35 million by December 31—plus a $37.5 million trailing twelve-month requirement by March 31, 2026. The extension buys time to showcase earnings potential. Yet cash hoarding above $20 million triggers mandatory prepayments.
8-K
Q2 sales up, EBITDA doubles
American Vanguard reported Q2 2025 net sales of $129 million, up 1% from $128 million last year, with adjusted EBITDA surging to $11 million from $6 million thanks to manufacturing tweaks and procurement gains that lifted gross margins to 31% from 29%. Inventory dropped $53 million year-over-year to $191 million, while debt eased to $189 million, signaling sharper operations amid easing ag destocking. The company holds firm on full-year revenue guidance of $535–$545 million and EBITDA of $40–$44 million. Transformation costs fell sharply, but debt refinancing looms.
10-Q
Q2 FY2025 results
American Vanguard swung to an operating profit of $4.4M in Q2 FY2025 ended June 30, 2025, up from a $9.2M loss a year earlier, while net sales edged 1% higher to $129.3M on steady U.S. crop and non-crop demand. Gross margins expanded to 31% from 29%, fueled by efficient factory runs and lower raw material costs, though YTD sales dipped 7% to $245.1M amid distributor destocking, yielding a slim $56K operating profit versus a $3.1M loss last year. Operating cash flow drained $39.8M, with free cash flow at -$40.8M after $1.0M capex, yet cash climbed to $14.5M and revolver availability hit $31.8M despite $189.5M debt at 8.18%. Diluted EPS of -$0.03 reconciles cleanly to 28.3M shares, no anti-dilution noted. Transformation costs plunged 78% to $1.6M, sharpening focus. Debt covenants were waived through year-end, but extension talks loom. Regulatory scrutiny from the MAHA Commission could crimp pesticide demand.
8-K
Annual meeting votes pass
American Vanguard Corporation's stockholders, at the July 2, 2025 annual meeting, elected nine directors—Marisol Angelini, Scott Baskin, Mark Bassett, Patrick Gottschalk, Emer Gunter, Douglas Kaye, Steven Macicek, Keith Rosenbloom, and Carmen Tiu—to serve until successors qualify. They also ratified Deloitte & Touche LLP as auditors for the year ending December 31, 2025, and approved executive compensation policies on an advisory basis. Votes favored all proposals overwhelmingly. Directors secure continuity.
8-K
NYSE compliance restored; Q1 results mixed
American Vanguard resolved its NYSE compliance issue on June 6, 2025, after filing delayed 10-K and 10-Q reports, regaining listing status amid internal control fixes. Q1 2025 sales fell 14% to $116 million with adjusted EBITDA at $3 million, hit by destocking, a canceled herbicide, Mexican agave weakness, and Australian drought—yet operating expenses dropped $5 million and net trade working capital improved $85 million versus last year. Management cut full-year guidance to $535–$545 million revenue and $40–$44 million adjusted EBITDA, eyeing a market recovery. Destocking hit historic lows.
IPO
Employees
Sector
Industry
BIOX
Bioceres Crop Solutions Corp.
1.92-0.08
CF
CF Industries Holdings, Inc.
84.15-1.95
CTVA
Corteva, Inc.
63.20-0.26
FMC
FMC Corporation
29.04-1.50
GNVR
Genvor Incorporated
2.00+0.10
LVRO
Lavoro Limited
1.38-0.04
MOS
Mosaic Company (The)
28.65-0.73
NTR
Nutrien Ltd.
56.44-0.57
SANW
S&W Seed Company
0.22-0.11
VRDR
Verde Resources, Inc.
0.09+0.00